lemoddepo 40 mg/1 ml suspenzija za injekciju
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - metilprednizolon - suspenzija za injekciju - 40 mg/1 ml - 1 ml suspenzije za injekciju sadrži: 40 mg metilprednizolon acetat
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
apretude
viiv healthcare b.v. - cabotegravir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 i 5.
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.
optiray 300 636 mg/1 ml rastvor za injekciju/ infuziju
pharmacol international d.o.o. - joversol - rastvor za injekciju/ infuziju - 636 mg/1 ml - 1 ml rastvora za injekciju/infuziju sadrži: 636 mg joversola (što odgovara 300 mg joda)
optiray 300 636 mg/1 ml rastvor za injekciju/ infuziju
pharmacol international d.o.o. - joversol - rastvor za injekciju/ infuziju - 636 mg/1 ml - 1 ml rastvora za injekciju/infuziju sadrži: 636 mg joversola, (što odgovara 300 mg joda)/ml
optiray 350 741 mg/1 ml rastvor za injekciju/ infuziju
pharmacol international d.o.o. - joversol - rastvor za injekciju/ infuziju - 741 mg/1 ml - 1 ml rastvora za injekciju/infuziju sadrži: 741 mg joversola, (što odgovara 350 mg joda)
optiray 350 741 mg/1 ml rastvor za injekciju/ infuziju
pharmacol international d.o.o. - joversol - rastvor za injekciju/ infuziju - 741 mg/1 ml - 1 ml rastvora za injekciju/infuziju sadrži: 741 mg joversola, (što odgovara 350 mg joda
optiray 350 741 mg/1 ml rastvor za injekciju/ infuziju
pharmacol international d.o.o. - joversol - rastvor za injekciju/ infuziju - 741 mg/1 ml - 1 ml rastvora za injekciju/infuziju sadrži: 741 mg joversola, (što odgovara 350 mg joda)
optiray 350 741 mg/1 ml rastvor za injekciju/ infuziju
pharmacol international d.o.o. - joversol - rastvor za injekciju/ infuziju - 741 mg/1 ml - 1 ml rastvora za injekciju/infuziju sadrži:741 mg joversola, (što odgovara 350 mg joda)